Prudent Drug Discovery Company
Low market cap (appox £13m at time of writing).
Issues shares very rarely (last placing nearly four years ago).
Has material interest in its work from larger partners (Pharmaxis).
Sold interest in LOXL2 programme for £5m to Pharmaxis in December.
Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest ...